I don't understand this. If it's the same drug for both trials, why would you partner for one and not the other. I doubt manufacture or end sales would be allocated to one condition and not the other.
Ann: Quarterly Appendix 4C and Activities Report, page-213
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
-0.015(2.46%) |
Mkt cap ! $329.8M | |||
| Open | High | Low | Value | Volume |
| 60.5¢ | 61.0¢ | 59.5¢ | $663.1K | 1.103M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 76433 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 86765 | 5 |
View Market Depth
| Last trade - 10.52am 21/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |